3
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6352 |
(-)-Dizocilpine maleate
C13737,(-)-MK 801 (Maleate),(-)-MK 801马来酸,(-)-MK 801 Maleate |
NMDAR; iGluR | Membrane transporter/Ion channel; Neuroscience |
(-)-Dizocilpine maleate ((-)-MK 801 (Maleate)) 是一种选择性且非竞争性的 N-甲基-D-天冬氨酸 (NMDA) 受体拮抗剂,Ki 为 211.7 nM。它是一种 Dizocilpine 的活性较低的 (-)-对映体,具有抗抑郁作用。 | |||
T6259 |
Dizocilpine
地佐环平,MK-801 |
NMDAR; iGluR | Membrane transporter/Ion channel; Neuroscience |
Dizocilpine (MK-801) 是一种选择性非竞争性NMDA 受体拮抗剂,Kd=37.2 nM,是一种抗惊厥剂。它通过与 NMDA 相关离子通道内的一个位点结合而起作用,从而阻止 Ca2+的流动。 | |||
T3320 |
Dizocilpine Maleate
(+)-Mk-801 Hydrogen Maleate,MK 801,地卓亚平马来酸盐,Dizocilpine hydrogen maleate,地佐环平马来酸盐,(+)-MK 801 maleate,(+)-MK 801 (Maleate) |
NMDAR; iGluR | Membrane transporter/Ion channel; Neuroscience |
Dizocilpine Maleate (MK 801) 是一种选择性和非竞争性的 NMDA 受体拮抗剂,Kd 值为 37.2 nM。它用于治疗 NMDA 受体可能发挥重要作用的多种神经退行性疾病或疾病。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |